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Purpose: The purpose of this study was to determine the relationship of CYP2B6 
genotype to the clinical response to meperidine in pediatric dental patients. 
Methods: Twenty-five patients, ASA I/ II, 45–92 months old, received an oral 
sedative regimen containing meperidine for dental treatment. The North Carolina Behavior 
Rating Scale (NCBRS) and Overall Effectiveness of Sedation Scale (OESS) were used to 
assess their behavior and sedation outcome. Saliva DNA samples were genotyped by PCR-
RFLP.   
   
viii  
Results: We found the following genotype distributions: homozygous wild-type 
1*1 (n = 8, 32%), heterozygous 1*6 (n = 13, 52%), and homozygous variant 6*6 (n = 4, 
16%). The genotypes were predictive of a significant decrease in the overall effectiveness 
of sedation.  
Conclusion: Variation in CYP2B6 appears to be predictive of less successful 
sedations; wild-type individuals experienced more successful sedations than the 
homozygous variant 6*6. Future research regarding the enzyme kinetics of meperidine is 
needed to determine the exact enzymatic function of CYP2B6 and its variants. 
  1 
 
 
 
 
INTRODUCTION 
 
 According to the American Academy of Pediatric Dentistry (AAPD) moderate 
sedation (formerly known as conscious sedation or sedation/analgesia) is defined as “drug-
induced depression of consciousness during which patients respond purposefully to verbal 
commands…either alone or accompanied by light tactile stimulation” 
1
. In 1996, a survey 
by Wilson et al of 1758 AAPD members found that 40% of members use sedation 1 to 5 
times per week and 20% use sedation more than 5 times per week.
2
  It is estimated that 
more than 1 million children have been sedated by pediatric dentists since 1985.
2
 
Meperidine (Demerol®) is commonly used for moderate sedation in pediatric 
dentistry. Meperidine’s popularity in pediatric sedation is due to its fast on-set of 
approximately 15 minutes following oral administration. Peak sedation is achieved in 
approximately 2 hours and subsides over several hours.
 3, 4 
Meperidine is an opioid 
analgesic that was originally developed as an anticholinergic drug.
5, 6
 It acts on the mu (µ) 
receptors found in the central nervous system (CNS) and on the neural elements in the 
bowel.
3, 7
 Its opioid analgesic properties include inducing sedation, reducing reaction to 
painful stimuli and reducing motor activity.
3
 Meperidine’s side effects include 
hypotension, histamine release, nausea and vomiting, and decreased sensitivity to CO2 
leading to respiratory depression.
4, 7
 Meperidine is primarily metabolized in the human 
liver by N-demethylation to form the active metabolite normeperidine (6-N-
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desmethylmeperidine), which is a potent stimulant of the CNS with no analgesic 
properties.
7, 8
 The accumulation of normeperidine can cause neurotoxicity and produce 
symptoms such as delirium, nervousness, tremor, muscle twitches and seizures.
7, 8
 
Adverse drug reactions (ADRs) are a problem. Annually in the United States just 
over 2 million ADRs are estimated to occur, with approximately 100,000 resulting in 
death.
9 
Meperidine may contribute to this problem is some patients. A review of pediatric 
dental adverse events and their contributing factors from 1969 through March 20, 1996 by 
Cote et al. found 95 reported incidents: 51 resulted in death, 9 in permanent neurologic 
injury, 21 in prolonged hospital stay without injury and 14 experienced no harm.
10
 Twenty-
nine of the 60 incidents resulting in death and permanent neurologic injury were related to 
various specialties in dentistry.
 10
  
In 2001, Leelataweedwud et al. examined 195 cases of conscious sedation in 
pediatric dentistry with the classic triple cocktail of chloral hydrate, meperidine and 
hydroxyzine.
11 
The study found a success rate of 72%, while 23% were unsuccessful and 
5% were aborted.
11
 There were 3% with adverse events reported which included vomiting, 
desaturation, prolonged sedation and apneic episodes.
11
 The incidence of meperidine 
ADRs is consistent with genetic variation being a partial causative factor. 
Reducing ADRs is especially important when administering drugs to children in an 
outpatient setting. Outpatient procedures requiring children to receive sedation include 
gastrointestinal procedures, MRI scans, dental rehabilitation, and procedures completed in 
the emergency department. The most commonly used opioid analgesics for moderate 
sedation and analgesia are fentanyl and meperidine.
12
 Common adverse effects of these 
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drugs, when used as single agents can include over-sedation, respiratory depression, 
mental clouding, delirium, seizures, hypotension, flushing, sweating and pruritis. While 
not lethal, these effects are common with and without significant co-morbidities. 
Practitioners today are unable to predict, without error, who will and who will not have an 
adverse drug reaction. Using pharmacogenomics to select medications could potentially 
increase therapeutic responsiveness from the 50% it is today to almost 75%, while 
dramatically reducing the number of ADRs occurring each year.
13 
Pharmacogenetics could 
revolutionize pediatric sedation, and lead to increased patient satisfaction and safety. 
The cytochrome P450 monooxygenase enzyme group is a multigene family of 
hepatic enzymes that are responsible for the oxidative metabolism of most medicines. 
Genetic variation in the metabolic activity of these enzymes can have a negative effect on 
drug efficacy and safety. Genetic polymorphisms in these and other enzymes can be used 
to guide drug treatment. Figure 1 shows the following isoenzymes which are responsible 
for the in vitro metabolism of the meperidine: CYP2B6, CYP3A4, and CYP2C19, with 
CYP2B6 being the major enzyme that metabolizes meperidine.
14
 In addition its action in 
the liver, CYP2B6 has also been identified in the human brain.
15, 16
  
The CYP2B6 gene is located on chromosome 19, between 19q12 and 19q13.2 and 
is composed of 9 exons.
17, 18, 19
 Haplotype analysis demonstrates the presence of multiple 
alleles including the most common form or wild-type CYP2B6*1, and the most common 
variant, CYP2B6*6.
20
 The activity of CYP2B6 varies between individuals and this 
variation has been shown to be genetic.
14
 The diagnostic variant in the haplotype 
CYP2B6*6, is a single nucleotide polymorphism of G to T in exon 4 that results in a 
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substitution of Gln to His at amino acid 172 (516G>T, Gln172His).
 21
 This change is 
associated with a significant loss of function as measured by enzymatic activity.
21
 This 
variation is clinically relevant. For example, the CYP2B6*6 variant has been reported to 
affect the pharmacokinetics of efavirenz (EFV), a first line medication for treatment of 
human immunodeficiency virus (HIV) patients.
20, 21
 Patients who are homozygous 
CYP2B6*6 experience more adverse neurological events such as fatigue and mood 
disorders when they are put on long term EFV therapy compared to those who are 
homozygous wild type.
21
 
  In pediatric dentistry, we often encounter children who are unable to tolerate dental 
procedures comfortably despite traditional behavior management techniques and adequate 
local anesthesia. These children require sedation in order to receive care.
1 
This group of 
patients, because of their age, is considered more susceptible to the adverse effects of 
sedatives and narcotics on the respiratory drive, loss of protective airway reflexes and 
airway obstruction.
1 
Currently, oral sedative agent selection is based on the patient’s 
behavior, weight, medical history, physical exam and anticipated duration of the dental 
procedures. Structured sedation protocols have shown to reduce morbidities and enhanced 
sedation safety for pediatric patients.
1
 However there remains an element of 
unpredictability of response to sedation. One source of variability is thought to be genetics.  
It is unknown at this time what affects the CYP2B6*6 allele may have on the 
pharmokinetics of meperidine. It may be associated with either an increase or decrease in 
enzymatic activity, which may have varying clinical effects such as slower drug clearance, 
resulting in prolonged sedation, or at the other end of the range excitability. The specific 
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aim of this study is to determine the relationship between the CYP2B6 genotype at this one 
loci and clinical response to meperidine in pediatric dental patients. 
  6 
 
 
METHOD AND MATERIALS 
 
Sample and data collection  
Twenty-five patients previously identified as requiring oral sedation for dental 
treatment were recruited to participate in our research from the VCU School of Dentistry 
Pediatric Dental Clinic. Patient ages ranged from 45 to 92 months at the time of treatment. 
All patients were ASA I or II. The patients received an oral sedative regimen containing  
meperidine combined with one or more of the following medicines: chloral hydrate, 
hydroxyzine (Vistaril®) and midazolam (Versed®).  
Informed consent for dental treatment under oral sedation, physical restraint and 
participation in the study were obtained from the parent/guardian. An assent form was 
obtained from patients who were 7 years or older for the saliva collection for CYP2B6 
genetic testing. Saliva has been shown to be a viable and noninvasive method for obtaining 
DNA for genetic analysis.
22
  
Prior to the administration of oral sedation medications baseline vital signs were 
obtained. After administration of the medications by the treating dental resident, the 
patients and their parents/guardian remained in the pre-op room for at least 30 minutes 
before the start of the dental procedure. Once in the treatment room, a blood pressure cuff 
and precordial stethoscope were applied and the patient was placed on a papoose board. 
Treatment began once all of the monitoring equipment was in place and the patient was 
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comfortable. The patient’s heart rate, blood pressure, and oxyhemoglobin saturation rate 
(SaO2) were recorded at five minute intervals. Respiratory status and breath sounds were 
monitored throughout the procedure via the precordial stethoscope by the treating pediatric 
dental resident.  
The behavior of the child during the treatment was recorded using the North 
Carolina Behavior Rating Scale (NCBRS) and the overall effectiveness of the sedation was 
rated using the Overall Effectiveness of Sedation Scale (OESS).
23, 24 
  Vital signs, 
physiological parameters and behavior scores were charted by a monitoring provider. Once 
the AAPD discharge criteria
1
 were met the parents/guardian were escorted into the 
treatment room to meet the patient. Post-operative instructions were given in verbal and 
written formats to the patients and their parents/guardian.  
Adverse events were defined as follows: desaturation was when the pulse oximeter, 
SaO2, reading was below 95%; apnea was when there is no breath sounds via precordial 
stethoscope and no visible sign of chest rise for greater than 25 seconds; excessive sedation 
was when the patient required more than 30 minutes to recover; seizure, nausea and 
vomiting.  
Data collection was standardized prior to the start of this research. All nine 
residents and full-time faculty at the VCU Pediatric Dental Department were trained and 
calibrated by assessing 10 videotaped sedations that were not part of this study. The 
calibration videos were of patients of record at VCU Pediatric Dental Department who 
needed sedation for dental treatment. Informed consents for videotaping, physical restraint 
with a papoose board and standard treatment during oral sedation were obtained from the 
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parent/guardian. The calibration training entailed watching the videos of 10 taped sedations 
and assessing each patient’s behavior based on the North Carolina Behavior Rating Scale 
(NCBRS) during critical events at every 5 minute intervals
 
(see Appendix 1). The Overall 
Effectiveness of Sedation Scale (OESS) was used to rate the overall success of the oral 
sedation appointment ranging from “successful to unsuccessful” depending on how the 
patient’s behavior affected the treatment outcome (see Appendix 1). The calibration study 
indicated significant agreement (Kappa = 0.60, p < .0001).
25
 
 
Genetic analysis 
For each patient, 2 ml of saliva was collected using Oragen DNA (OG-300) self 
DNA collection kit before and after the treatment. The patient’s saliva was collected and 
the genetic analysis of CYP2B6 was done at a later date.  
The DNA was extracted manually from 2ml of un-induced saliva by using QIAamp 
DNA Blood Mini Kit (Valencia, CA, USA), following the manufacturer’s instructions. 
PCR amplified the exonic the *6 variable region of CYP2B6.
21 
 
The genotyping analysis was done with restriction fragment length polymorphism 
(RFLP). To generate the CYP2B6 526bp product, the following primers were used: 
2B6*6F 5' - GGT CTG CCC ATC TAT AAA C - 3' and 2B6*6R 5' - CTG ATT CTT CAC 
ATG TCT GCG - 3'. The PCR product was digested with Fermentas BseNI restriction 
endonuclease enzyme. The digestion of the CYP2B6*6 variant allele 516TT amplicons 
yielded two fragments of 23 and 503 bp and that of the CYP2B6*1 wildtype allele 516GG 
amplicons resulted in 3 fragments of 23, 236 and 267 bp. The digestion products were 
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separated on a 2% aragose gel using electrophoresis, and banding patterns were visualized 
under UV light then photodocumented.  
 
Statistical Analyses 
To compare the observed genotype frequencies with those expected under Hardy-
Weinberg equilibrium, a chi-square test with one degree of freedom was used. The primary 
aim was to test the association between CYP2B6 genotypes (homozygous for the normal 
allele = 1*1, heterozygous = 1*6, and homozygous for the variant allele = 6*6) and clinical 
response (behavior and sedation effectiveness), using data from the North Carolina 
Behavior Rating Scale and the Overall Effectiveness of Sedation Scale.  
The groups were compared using a chi-square analysis for nominal outcomes and 
analysis of variance (ANOVA) for continuous outcomes. Multivariable analyses were 
accomplished using a repeated-measures mixed-model ANOVA (SAS software. JMP8.0 or 
SAS9.2, Cary NC). The study was approved by the Virginia Commonwealth University 
Institutional Review Board Committee on Investigations Involving Human Subjects. All 
clinical data were collected in the VCU Pediatric Dental Clinic and the DNA isolation was 
performed at the School of Pharmacy in the laboratory of Dr. Bukaveckas.  
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RESULTS 
 
Preliminary analyses 
The demographic characteristics of the patients (n = 25) are shown in Table 1. The 
patients were primarily African Americans (n = 19), with 5 Caucasians and 1 was marked 
of other race. There were 16 females and 9 males. The patient’s ages ranged from 45 
months to 92 months with an average age of 63.5 months at time of treatment. The 
majority of subjects (68%) were ASA I status, while the rest were ASA II. The mean time 
of treatment duration was 25.1 minutes with a range of 5 minutes to 63 minutes. The 
patients were categorized into three genotypes and identified as: 1*1 for homogenous wild-
type allele CYP2B6 (n = 8, 32%), 6*6 for homogenous variant allele (n = 4, 16%), and 1*6 
for heterozygous allele (n = 13, 52%). These proportions were not different than the 
expected values (25%, 50%, 25%, chi-square = 1.32, df = 2, p > 0.5) under the Hardy-
Weinberg equilibrium. Comparing the demographic characteristics in Table 1, there were 
no significant differences between the genotypes (ps > 0.09). 
 The medications used in the patients are described in Table 2. The triple-cocktail 
combination of meperidine, midazolam, hydroxyzine was used in 68% of the cases. The 
second most common drug regimen was meperidine, midazolam, and chloral hydrate, used 
in 20% of the cases. The meperidine and midazolam combination and meperidine and 
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hydroxyzine combination were each used once. In one case, Propofol® was used after 
converting to intravenous sedation (IVS) due to failed oral sedation.  
 In the study cohort (n=25), 48% received restorations (n = 12), 12% extractions (n 
= 3), 28% both restorations and extractions (n = 7), and in 12% of the cases the planned 
procedures were not performed and the process was aborted (n = 3). There were no 
instances of apnea or nausea, one instance of vomiting, two instances of desaturation and 
three instances of excess sedation meaning the patients too longer than 30 minutes post-op 
for recovery. 
 
Primary analyses 
 The primary goal of the study was to compare the overall effectiveness of oral 
sedation between three genotype groups: CYP2B6*1*1, CYP2B6*1*6 and CYP2B6*6*6. 
Table 1 shows the number of individuals in each genotype and sedation effectiveness 
combination. The genotype groups showed a significant difference in the overall 
effectiveness (Wilcoxon rank-sum chi-square = 10.3, df = 2, p = 0.0058). As may be seen 
in the table, the CYP2B6*1*1 genotype had the most effective success scores (median 
effectiveness = 2) while the homozygous variant, CYP2B6*6 genotype had the worst 
(median = 4). 
 A stepwise regression analysis of the demographic characteristics and drug 
regimens was performed to determine if the difference between genotypes could also be 
explained by a confounding factor. Only Vistaril (p = 0.17) and Propofol (p = 0.17) 
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emerged as potential confounders (using an alpha cut-off of 0.2). Including these in the 
model did not change the conclusion that effectiveness differed by genotype. 
 
Secondary analyses 
 The secondary analysis focused on outcomes that were assessed on repeated 
occasions during the course of each child’s procedure. These outcomes were: NCBRS,  
HR, Dia-BP, Sys-BP, and SaO2. Each of these outcomes were analyzed separately with a 
repeated-measures ANOVA with the following factors in the model: Event type (Baseline, 
preOp, IntraOp, and PostOp), genotype (the three values), and an event*genotype 
interaction.  
 The NCBRS was recorded on 168 occasions (between 0 and 14 times per patient) 
and had a mean = 1.95, SD = 1.10. NCBRS was not assessed during the post-operative 
period. The results of the repeated-measures ANOVA indicated that NCBRS did vary 
across event types (p < .0001), that the genotypes did differ (p = 0.0064) and that the event 
differences did not vary with genotype (p > .5, see Table 4). The estimated mean NCBRS 
for each genotype and event is also shown in Table 4 and Figure 2. At baseline, the three 
genotypes are not significantly different (uncorrected p-value = 0.22) but at pre-operative 
phase (PreOp) they have become different (p = 0.0410). At the intraoperative period 
(IntraOp), the genotypes are different (p = 0.0007). Within the genotype 1*1, there was no 
difference across the events (p = 0.14) but within the 1*6 genotype there was a significant 
trend (p = 0.0020) and within the 6*6 group as well (p = 0.0035). 
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 The 1*1 individuals behaved with an NCBRS of 1.14 to 1.64, meaning they were 
relatively quiet and had some inconsequential movements throughout the procedures. 
While at the other end, those with genotype 6*6 had an average NCBRS of 2.25 baseline 
and 3.71 intraoperatively. Those who possess 1*6 genotype, their NCBRS was 1.46 at 
baseline and 2.27 during intra-op, which are between the values of those that have 1*1 and 
6*6 genotypes.  
  Another way to perform this comparison is to consider the NCBRS as an ordered 
multinomial response. The number and percentage are shown in Table 5. The traces for 
each patient in each genotype group are shown in Figure 2. As is seen, in the genotype 1*1 
group, all but one subject are NCBRS=1 at baseline and PreOp and only a few of the 
subjects increase averages between 2-3 by IntraOp. The 1*6 group have traces that also 
begin in the 1-2 range and then increase to the 2-3 range, or in some cases as high as 
NCBRS=3 or 4. There are only n = 4 subjects in the 6*6 genotype and many seem to begin 
at higher levels and all end in averages in ranges near 3-4. 
 The ordered multinomial outcomes may be modeled using a cumulative logit and 
the GEE method for accounting for repeated measures (SAS GENMOD procedure). As is 
seen in Table 6, there remain differences between the Events (p < 0.03) but the genotype 
difference is less clear (p > 0.07). 
The heart rate, (HR) was recorded on 300 occasions (between 2 and 19 times per 
patient) and had a mean = 99.7, SD = 20.1. The results of the repeated-measures ANOVA 
indicated that HR did vary across event types (p < .0001), that the genotypes did not differ 
(p > 0.5) and that the event differences did not vary with genotype (p > 0.5, see Table 3). 
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The estimated mean heart rate for each event is also shown in Table 7 and Figure 6. 
Tukey’s HSD indicated that the PreOp mean was not significantly different than any of the 
others and that each of the others was significantly different from one another. 
 The systolic blood pressure (Sys-BP) was recorded on 285 occasions (between 2 
and 18 times per patient) and had a mean = 121.5, SD = 21.2. The results of the repeated-
measures ANOVA indicated that Sys-BP did vary across event types (p = .004), that the 
genotypes did not differ (p > 0.8) and that the event differences did not vary with genotype 
(p > 0.7, see Table 8). The estimated mean systolic BP for each event is also shown in 
Table 8 and Figure 7. Tukey’s HSD indicated that only the PreOp and IntraOp values were 
significantly different from one another. 
 The diastolic blood pressure (Dia-BP) was recorded on 285 occasions (between 2 
and 18 times per patient) and had a mean = 67.5, SD = 13.8. The results of the repeated-
measures ANOVA indicated that Dia-BP did vary across event types (p = .002), that the 
genotypes did not differ (p > 0.8) and that the event differences did not vary with genotype 
(p = 0.152, see Table 5). The estimated mean dia-BP for each event is also shown in Table 
9 and Figure 7. Tukey’s HSD indicated that the IntraOp and PostOp values were not 
different from one another, but that they were significantly higher than PreOp. Baseline 
values were not different than any other event. 
 The oxygen saturation, SaO2, was recorded on 296 occasions (between 2 and 19 
times per patient) and had a mean = 98.6, SD = 1.4. Since SaO2 was so strongly skewed, 
with 90% of the values above 98, this outcome was analyzed on the log-scale and then the 
summary results back transformed to the original scale. The results of the repeated-
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measures ANOVA indicated that SaO2 did not vary across event types (p > .2), that the 
genotypes did not differ (p > 0.6) and that the event differences did not vary with genotype 
(p > .7, see Table 10). The estimated mean SaO2 for each event is also shown in Table 10 
and Figure 8. There were two cases where patients experienced desaturation (<95% SaO2). 
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DISCUSSION 
 
Genetic finding: 
 In vitro studies of CYP2B6 have shown that all variant alleles encode functionally 
active proteins.
26, 27
 The mean protein expression level of those who were heterozygous, 
1*6, compared to that of the wild type, 1*1, did not show a significant reduction (Lang et 
al 2000). However, there was a reduction of approximately 50% in protein expression for 
those who were homozygous 6*6.
26
 This was as expected from a clinical efavirenz (EFV) 
study where they found that homozygous for the *6 variant allele had more than three-fold 
higher plasma drug concentration than those who were wild types.
21
 In a study by 
Rodriguez-Novoa et al. 40% homozygous 6*6 and 19% of hetrozygous had EFV 
concentration >4µg/mL, which is the toxic level. Nearly 20% of homozygous 1*1 and 2% 
of homozygous 6*6 showed subtherapeutic level of EVF of <1µg/mL.
28
 The clinical 
relevance to their research was the individuals who carried the wild type allele had 
subtherapeutic concentration of EFV and were at risk for treatment failure; in contrast, 
those who were homozygous 6*6 experienced neurological adverse effects more 
frequently. As expected, a reduction in enzymatic function was more likely to lead to an 
accumulation of EFV plasma concentration within the toxic range. 
The homozygous variant CYP2B6*6, homozygous wild-type CYP2B6*1, and 
heterozygous CYP2B6 genotypes were present in 16%, 32% and 52% of our population, 
respectively. There were no statistical significant differences found between the 
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demographic characteristics and the genotypes (ps > 0.09). Interestingly, our study results 
showed the opposite of what was expected based on in vitro studies of CYP2B6 function.  
There was a statistical significance in overall effectiveness of sedation outcome, (chi-
square = 10.3, df = 2, p = 0.0058) between the genotypes and their overall sedation 
success. Table 3 showed that the homozygous wild-type, 1*1, had an average of overall 
effectiveness score of 2, which translated to a moderately successful sedation with 
moderate amount of crying and movement. In patients who were homozygotes for 6*6, 
they had a mean score of 4 which was interpreted as an unsuccessful sedation outcome, 
with continuous crying and movements throughout sedation, treatment performed with 
difficulty, and treatment progression was hindered.  
One possible explanation to the phenotypes observed in our study was the 
possibility of one amino acid substitution of Gln172His mutation caused by natural single-
nucleotide polymorphism enhancing the enzymatic activity of CYP2B6*6. Ariyoshi et al 
in vitro enzyme kinetic study demonstrated that wild-type CYP2B6 followed the classical 
hyperbolic Michaelis-Menten kinetics while the variant allele CYP2B6*6 showed the 
sigmoidal kinetics with a higher Vmax value compared to that of the wild-type enzyme.
29
 
Sigmoidal kinetics plot indicates cooperative binding of substrate to the active site which 
means that the binding of one substrate molecule affects the binding of subsequent 
substrate molecules. Allosteric activation by its substrate, also called homotropic 
cooperativity, is also seen in CYP3A4 mediated drugs metabolism.
29
  This autoactivation 
phenomenon appears dependent on the substrate.
29
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CYP2B6*6 catalytic activity may be enhanced with meperidine. This would 
explain the phenotypes observed in our study population. The patients who were 
homozygous 6*6 may have metabolized meperidine at a faster rate, leading to 
accumulation of normeperidine, which is associated with symptoms of neurotoxicity and 
CNS excitation. Furthermore, blood levels of normeperidine:meperidine AUC ratio is 
higher when it is delivered orally compared to the parenteral route.
30, 31, 32
  While delirium, 
tremor, muscle twitches and seizures did not occur in the study, the NCBRS for patients 
with the variant allele were classified as “wild” meaning defiant with undesirable 
behaviors (crying, screaming, head movement, torso movement, hand movement or foot 
movement at critical events). Such phenotypes can be interpreted as symptoms of CNS 
stimulation by normeperidine. 
It appears that CYP2B6 and its variants activity may not be generally predictable 
by genetic diagnosis and is dependent upon their substrate. Our research showed that 
future investigations will be needed to exactly determine the enzyme CYP2B6*6 
properties toward meperidine. Future studies involve CYP2B6 variants and meperidine 
pharmacokinetics may help to explain whether there is an increase in normeperidine 
concentration in plasma and in peripheral blood mononuclear cells due to enhanced 
enzymatic activity caused by autoactivation.  
 
Behavioral findings 
This study design fostered a reliable behavior assessment since each rater (dental 
resident/faculty) was calibrated using the NCBRS and the OESS scales. The stepwise 
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analysis of the demographic characteristic and drug regimens was performed and shown 
that the drug regimen (Table 2) did not change the conclusion that the overall effectiveness 
differed by genotype. At baseline, the NCBRS did not differ between the three genotypes. 
However, at intraoperative phase, there was a difference between 3 groups as shown in 
Table 4 and Figure 9. Within the wild-type allele, there was no difference across the events 
(p=0.14). However, within the 1*6 and 6*6 variant alleles, there was a significant trend 
difference in the events, p = 0.0020 and p = 0.0035, respectively. The NCBRS for group 
1*1 started at 1 at baseline and increased to 2-3 by intraoperative phase compared to group 
1*6 and 6*6 which ended with a rating of 3-4 during intraoperative phase.  
The overall effectiveness of sedation score may be high for some patients. If the 
patient was extremely vocal during the intraoperative length of the treatment, the treating 
dentist may have rated the sedation in a more negative manner despite the fact the child 
remained still and treatment proceeded without complications.  
  
Physiologic findings 
In the study population (n=25), 12% were aborted due to the patient’s behaviors. 
Adverse events were reported as followed: 3 cases of excessive sedation (>30 minutes for 
recovery), 1 case of vomiting, and 2 cases of desaturation. There were no instances of 
apnea or nausea.  In pediatric patients, nausea does not always procede vomit, which could 
occur instantaneously without warning. 
 In oral sedation, pediatric dental patients often cry and struggle during treatment 
therefore it is not uncommon to see “false alarms” meaning oxygen desaturation associated 
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with movements. These “false alarms” should not be overlooked. In oral sedation, 
desaturation, when the pulse oximeter reading is <95%, could happen due to many reasons 
including hypoxia, hypoventilation, excessive patient movements that cause mechanical 
interference, or pressure that the operator exerts on the mandible creating a mechanical 
airway obstruction. In our study, the desaturation was found in two cases which was 
promptly adjusted back to normal readings of >95% SaO2 saturation after adjusting the 
position of the mandible and the pulse oximeter monitor. 
Vital signs (heart rate, BP, and SaO2) were not statistically significant between the 
different genotypes. The tendency for heart rate to increase with different event types, such 
as baseline to intraoperative phase, was seen. Such a finding can be explained as during 
intraoperative phase, which was when the patient was stimulated with local anesthetic 
injection, rubber dam placement and dental operative procedures, the heart rate could 
increase. Of critical importance was the average heart rate, 124.2 beats/minute, through out 
the sedation fell within the normal range for children age 3 – 5, which is 80-125 
beats/minute. In addition, the average systolic pressure was 98.52 during intraoperative 
phase, which is also within the normal limits of systolic pressure for children age 3 – 5, 
which is 100 mmHg. 
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CONCLUSION 
 
Many studies have focused on parameters maximizing sedation success while 
minimizing ADRs associated with oral sedation medicines. However, at this time, no 
studies have looked into the genetic component to oral sedation medicine, specifically 
meperidine, and the sedation outcomes. We found that after the administration of oral 
sedation regimens containing meperidine, individuals who carry the homozygous allele 
CYP2B6*6 had less successful sedation outcomes and less desirable behaviors compared 
those who were wild-type and heterozygous, who experienced better sedation outcomes. 
While meperidine, at the recommended dosage, is considered safe for oral sedation, the 
usefulness of CYP2B6 genetic analysis to personalize medicine may increase patient safety 
and satisfaction.  
Genotyping patients for the variant allele CYP2B6*6 prior to receiving meperidine 
as an oral sedative for dental treatment in young children may prove to be important for 
identifying individuals with genetic predisposition for sedation failure, unnecessary 
anesthesia risks, economical, physical and emotional distress for both the child and the 
parent. Further research investigating CYP2B6 and its variants exact enzymatic function 
with respect to meperidine will contribute to the clinical significance of this enzyme. 
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Table 1: Demographic Characteristics 
Characteristic n %
Race
AA 19 76
C 5 20
O 1 4
Ethnicity
H 2 8
N 23 92
Gender
F 16 64
M 9 36
ASA
1 17 68
2 8 32
Wt (kg)
Mean 23.0
SD 6.5
Min. 15
Max 38
Duration of tx (min)
Mean 25.1
SD 17.0
Min. 5
Max 63
Age (years)
Mean 4.8
SD 1.1
Min. 3
Max 7
Age (months)
Mean 63.5
SD 13.1
Min. 45
Max 92  
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Table 2: Medications 
Medications n %
Drug regime
Dem Vis Ver 17 68
Dem Vis CH 5 20
Dem Ver 1 4
Dem Vis 1 4
Dem Vis Ver CH Pro 1 4
Local
none 6 24
L+epi 11 44
L+epi Sept 2 8
Sept 6 24
N2O use
N2O 21 84
none 4 16  
Abbreviations: Dem = Demerol, Vis = Vistaril, Ver = Versed, CH = Chloral hydrate, Pro = 
Propofol, L = Lidocaine, Sept = Septocaine, N20 = Nitrous oxide. 
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Table 3: Comparing Overall Effectiveness 
1 2 3 4 Median
1*1 3 3 2 2
1*6 4 4 5 3
6*6 1 3 4
Overall EffectivenessCYP2B6 
genotype
 
 
   
29  
Table 4: Analysis of NCBRS 
Source df Num. df Den. F p-value
Event 2 141.40 12.90 <.0001
Genotype 2 25.36 6.20 0.0064
Event*Genotype 4 141.40 0.77 0.5437
Event LS Mean SE
Genotype 1*1
Baseline 1.14 0.38 0.39 1.90
PreOp 1.14 0.38 0.39 1.90
IntraOp 1.64 0.26 1.10 2.19
Genotype 1*6
Baseline 1.46 0.31 0.84 2.07
PreOp 1.55 0.29 0.98 2.13
IntraOp 2.27 0.20 1.85 2.70
Genotype 6*6
Baseline 2.25 0.50 1.25 3.25
PreOp 2.75 0.50 1.75 3.75
IntraOp 3.71 0.38 2.94 4.49
95% CI
 
   
30  
Table 5: Observed Counts and Percentages for each category of NCBRS outcome. 
Event 1 2 3 4 Total
Baseline 6 (86%) 1 (14%) 0 (0%) 0 (0%) 7
PreOp 6 (86%) 1 (14%) 0 (0%) 0 (0%) 7
IntraOp 28 (61%) 10 (22%) 5 (11%) 3 (7%) 46
Total 40 (67%) 12 (20%) 5 (8%) 3 (5%) 60
Baseline 6 (60%) 3 (30%) 1 (10%) 0 (0%) 10
PreOp 8 (67%) 2 (17%) 1 (8%) 1 (8%) 12
IntraOp 25 (41%) 13 (21%) 16 (26%) 7 (11%) 61
Total 39 (47%) 18 (22%) 18 (22%) 8 (10%) 83
Baseline 1 (25%) 1 (25%) 2 (50%) 0 (0%) 4
PreOp 1 (25%) 0 (0%) 2 (50%) 1 (25%) 4
IntraOp 2 (12%) 2 (12%) 2 (12%) 11 (65%) 17
Total 4 (16%) 3 (12%) 6 (24%) 12 (48%) 25
Genotype 1*6 (n = 13)
Genotype 6*6 (n = 4)
Genotype 1*1 (n = 7)
NCBRS
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Table 6: Multinomial Analysis of NCBRS 
Source df Chi-sq. p-value
Event 2 7.41 0.0246
Genotype 2 5.19 0.0748
4 3.16 0.5306Event*Genotype  
Predicted Percentages for each outcome: 
Event 1 2 3 4 Total
Baseline 86 8 4 1 100
PreOp 86 8 4 1 100
IntraOp 61 20 13 6 100
Baseline 64 19 12 5 100
PreOp 66 18 11 5 100
IntraOp 40 25 23 13 100
Baseline 32 24 27 17 100
PreOp 18 19 32 31 100
IntraOp 6 9 25 60 100
Genotype 1*1 (n = 7)
Genotype 6*6 (n = 4)
Genotype 1*6 (n = 13)
NCBRS
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Table 7: Analysis of Heart Rate 
Source df Num. df Den. F p-value
Event 3 271.40 8.21 <.0001
Genotype 2 25.68 0.55 0.5863
Event*Genotype 6 271.10 0.88 0.5098
Event LS Mean SE
Baseline 88.30 4.36 79.62 96.98
PreOp 95.42 4.53 86.41 104.42
IntraOp 104.32 3.42 97.32 111.32
PostOp 98.55 3.44 91.51 105.59
95% CI
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Table 8: Analysis of Systolic Blood Pressure 
Source df Num. df Den. F p-value
Event 3 255.00 4.52 0.0042
Genotype 2 23.62 0.12 0.8849
Event*Genotype 6 254.70 0.64 0.7007
Event LS Mean SE
Baseline 113.86 5.31 103.29 124.42
PreOp 112.78 4.89 103.01 122.56
IntraOp 124.02 3.96 115.90 132.14
PostOp 118.11 4.00 109.91 126.31
95% CI
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Table 9: Analysis of Diastolic Blood Pressure 
Source df Num. df Den. F p-value
Event 3 258.80 5.02 0.0021
Genotype 2 27.71 0.14 0.8686
Event*Genotype 6 258.60 1.59 0.1515
Event LS Mean SE
Baseline 62.46 3.35 55.85 69.08
PreOp 61.18 3.01 55.22 67.13
IntraOp 68.83 2.15 64.46 73.20
PostOp 70.31 2.18 65.88 74.75
95% CI
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Table 10: Analysis of Oxygen Saturation 
Source df Num. df Den. F p-value
Event 3 272.50 1.40 0.2421
Genotype 2 31.77 0.38 0.6847
Event*Genotype 6 272.70 0.62 0.7139
Event LS Mean
Baseline 98.57 97.91 99.24
PreOp 98.23 97.54 98.92
IntraOp 98.52 98.09 98.94
PostOp 98.83 98.40 99.25
95% CI
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Figure 1. CYP450 isozymes responsible for meperidine metabolism. As illustrated in the 
figure, it has been demonstrated in vitro that Cytochrome P450, family 2, subfamily B, 
polypeptide 6 (CYP2B6) is the enzyme primarily responsible for metabolism of 
meperidine
 14
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Figure 2: NCBRS 
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Figure 3: Traces of NCBRS for patients with genotype 1*1 
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Figure 4: Traces of NCBRS for patients with genotype 1*6 
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Figure 5: Traces of NCBRS for patients with genotype 6*6
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Figure 7: Systolic Blood Pressure 
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Figure 8: Diastolic Blood Pressure 
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APPENDIX A 
 
Behavior rating scales 
The North Carolina Behavior Rating Scale and Overall Effectiveness of Sedation 
Scale were used to assess clinical response to meperidine and compare the relationship of 
CYP2B6 genotype and clinical response to meperidine. This appendix serves as a 
description of these scales. 
North Carolina Behavior Rating Scale (behavior): 
 The North Carolina Behavior Rating Scale (NCBRS) allows the practitioner and 
assistant to assess behavior at critical events of the procedure. Behavior ranging from quiet 
and cooperative (1) to wild and defiant (4) is scored at critical events.** 
1. Quiet: patient is quiet and/ or sleeping with only extraneous, inconsequential 
movements  
2. Annoyed: patient is cooperative for treatment, but with one or two of the undesirable 
behavior* 
3. Upset: patient is noticeably disturbed, with two to three undesirable behaviors* making 
treatment difficult but possible  
4. Wild: patient is extremely defiant with presence of all undesirable behaviors* making 
treatment extremely difficult.  
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* An undesirable behavior includes crying, screaming, head movement, torso movement, 
hand or foot movements at critical events** 
** Critical events: local anesthetic delivery (L), rubber dam placement (R), operative phase 
(O) such as bur penetrating tooth to rubber dam removal and extraction, IV conversion (C).  
 
Overall Effectiveness of Sedation Scale.  
1. Successful: Patient slept throughout procedure with only minimal crying/ movement at 
critical events* 
2. Moderately successful: Successful sedation with moderate amount of crying and 
movement but behavior did not hinder the progress of sedation 
3. Mildly successful: Treatment was accomplished as planned, but due to screaming/ 
combative movements throughout the sedation; the progression of portions of the 
treatment were hindered 
4. Unsuccessful: Continuous crying/movement throughout sedation; treatment was 
performed with difficulty; the progression of all treatment was hindered 
 
   
47  
 
 
VITA 
 
Sally Sang Guot Hua was born on January 13
th
, 1980 in Saigon, Vietnam. In 2000, 
she became a naturalized citizen of the United States of America. She graduated from 
Braintree High School, Braintree, MA in 1998. She attended Mount Holyoke College, 
South Hadley, MA and received her Bachelor of Arts, cum laude, in Biology in 2002. She 
also obtained a graduate certificate in Information Technology from the University of 
Queensland, Brisbane, Queensland, Australia in 2003. Dr. Hua, a Dean Scholar, received 
her Doctor of Dental Medicine from the University of Pennsylvania School of Dental 
Medicine in May of 2007.  
 
